To sign up for Analytiqa's free weekly newsletter, please enter your details below.
Analytiqa will not share this information with third parties.
Will continue to base supply chain support staff in North Carolina
Eisai has entered into a definitive agreement to transfer ownership of its Research Triangle Park (RTP) manufacturing campus to Biogen Inc. This arrangement expands upon the capacity-sharing manufacturing alliance Eisai and Biogen have had in place at the RTP facility since early 2013.
Under this new agreement, Biogen will continue to manufacture oral solid-dose products for Eisai. In addition, Eisai has entered into a new manufacturing agreement whereby Biogen will manufacture Eisai's parenteral products.
The property ownership transfer comprises all buildings on the campus. The parenteral facility will be transferred immediately upon closing of the transaction and the oral solid-dose facility will be transferred after the expiration of an existing short-term lease.
As part of this arrangement, Eisai anticipates approximately 100 employees will be offered employment at Biogen, effective upon deal closing.
While Eisai's manufacturing footprint is changing, the Company remains committed to having supply chain and manufacturing capabilities in the US. Eisai will continue to base its global partnership management, quality assurance, supply chain and business support staff in North Carolina to manage a seamless supply chain.
These functions will remain on the current RTP campus for a six-month transition period until Eisai has secured new office space. In addition, the Company will continue to manufacture product at its facility in Baltimore, MD.